Panacea Acquisition Corp 뉴스 - NUVB | 주식 뉴욕 증권거래소

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by...

Form PRER14A - Preliminary Proxy Soliciting materials

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial...

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by...

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025...

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches...

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025...

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

NUV-1511 is the Company’s first drug-drug conjugate (DDC) to enter the clinic Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Looks decent, I’ve been building a position around $3 lately.

NUVB.............................................https://stockcharts.com/h-sc/ui?s=NUVBB&p=W&b=5&g=0&id=p86431144783

👍️0

gail 10 월 전

looking strong a/h trading

👍️0

glenn1919 10 월 전

NUVB..............................https://stockcharts.com/h-sc/ui?s=NUVB&p=W&b=5&g=0&id=p86431144783

👍️0

gail 10 월 전

busting 4 bucks now, weeee!!

👍️0

TrendTrade2016 10 월 전

NUVB...COMING OUT OF A MONTHLY TIGHT BAND...THATS WHY THE MONSTER MOVE!!!

👍️0

gail 10 월 전

i must say, i have seen…….

…

you on many stocks you hated, but im relieved to see you like this one. that says something.

👍️0

TrendTrade2016 10 월 전

SUPER THIN....THE POWER OF A WEEKLY BREAK OUT...BULLISH AS FUC

👍️0

TrendTrade2016 10 월 전

NUVB...HERE COMES 4 DOLLA

👍️0

gail 10 월 전

it does move well, daily!

👍️0

TrendTrade2016 10 월 전

nuvb...here we go....bio beast

👍️0

TrendTrade2016 10 월 전

NUVB...MONSTA

👍️0

tw0122 10 월 전

New price target $10 by Jeffries from $1.40

👍️0

TrendTrade2016 10 월 전

nuvb...big gapper

👍️0

TrendTrade2016 10 월 전

NUVB new 52 week high

👍️0

Monksdream 11 월 전

NUVB new 52 week high

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Panacea Acquisition Corp (NUVB)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

NUVB 뉴스

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Form PRER14A - Preliminary Proxy Soliciting materials

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

NUVB Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Panacea Acquisition Corp (NUVB) 뉴스

Panacea Acquisition Corp (NUVB)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

NUVB 뉴스

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Form PRER14A - Preliminary Proxy Soliciting materials

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

NUVB Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거